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Abstract
Background: Infection represents a frequent complication among patients in Intensive Care Units
(ICUs) and mortality is high. In particular, the incidence of fungal infections, especially due to
Candida spp., has been increasing during the last years.
Methods: In a retrospective study we studied the etiology of candidemia in critically ill patients
over a five-year period (1999–2003) in the ICU of the San Martino University Hospital in Genoa,
Italy.
Results: In total, 182 episodes of candidaemia were identified, with an average incidence of 2.22
episodes/10 000 patient-days/year (range 1.25–3.06 episodes). Incidence of candidemia increased
during the study period from 1.25 in 1999 to 3.06/10 000 patient-days/year in 2003. Overall, 40%
of the fungemia episodes (74/182) were due to C.albicans, followed by C. parapsilosis(23%),
C.glabrata (15%), C.tropicalis (9%) and other species (13%). Candidemia due to non-albicans species
increased and this was apparently correlated with an increasing use of azoles for prophylaxis or
empirical treatment.
Conclusion: The study demonstrates a shift in the species of Candida causing fungemia in a
medical and surgical ICU population during a 5 year period. The knowledge of the local
epidemiological trends in Candida  species isolated in blood cultures is important to guide
therapeutic choices.
Background
Candida is an increasing cause of bloodstream infection
(BSI), causing significant mortality and morbidity, espe-
cially in non-neutropenic critically ill patients. Its overall
incidence raised fivefold in the past ten years and Candida
spp. is currently between the fourth and the sixth most
common nosocomial bloodstream isolate in American
and European studies [1,2]. Despite the availability of
effective antifungal therapy, mortality in the last decade
remained high, ranging from 36% to 63% [3]. In terms of
species of Candida, recently, a shift towards non-albicans
species was reported by some authors especially in hema-
tological and transplanted patients [4-7]. Some of these
emerging species has been correlated with increased viru-
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lence [8], and sometimes, but not always, with increased
mortality [9]. An increasing role for non-albicans species
was also noticed in studies performed among ICU
patients, although the issue is somewhat controversial
[3,10-12].
As shown by the SENTRY antimicrobial surveillance pro-
gram [1], C. albicans is still the species most frequently iso-
lated in BSI [13,14], while in other groups of patients non-
albicans species have surpassed C.albicans as a cause of
candidemia.  C.parapsilosis  and  C.tropicalis  are isolated
more frequently than C.albicans in some European and
Latin American centres [15].
A reduced antifungal susceptibility in non-albicans species
and a correlation with routine fluconazole prophylactic
use has been suggested [5,16]. Intrinsic and emerging
resistance of non-albicans species to azoles actually repre-
sents a major challenge for empirical therapeutic and pro-
phylactic strategies [17].
We have performed a retrospective study of Candida spp.
BSI in the ICU of the San Martino University Hospital, in
Genova, Italy, between 1999 and 2003, with the double
aim of understanding if any change was detectable in the
distribution of the various Candida species as cause of BSI
over the years and of estimating whether this change, if
existing, was correlated with the use of fluconazole for
prophylaxis or therapy.
Methods
The ICU of the San Martino General Hospital in Genova,
Italy, is a mid-size medical and surgical unit with 18 beds
and about 500 admissions per year. Patients who devel-
oped a clinically and microbiologically documented can-
didemia were identified through a microbiological
laboratory survey and data were recorded in an electronic
data base. The patients chart review was performed in
order to identify clinically relevant episodes. Candidemia
was defined as at least one positive blood culture yielding
Candida spp. in a patients with fever or other clinical signs
of infection. Nosocomial candidemia was defined as a
candidemia occurring at least 48 h after admission. Dur-
ing the study period there were no changes in microbio-
logical laboratory techniques. Candida species were
isolated from blood using BACTEC 860 system (Becton
Dickinson, INC, Sparks, MD). The species were identified
using API-32C system (bioMerieux Vitek, Inc, St. Louis,
MI). Frequencies and descriptives of demographic and
clinical characteristics of the patient population were
determined.
All patients were evaluable for the inclusion in this study.
The Chi-square-test or the Fisher Exact-test were used to
compare categorical variables. Chi-square-test for trend
was used to estimate the relationship between albicans
and non-albicans isolation rates during the years of study.
In order to understand whether or not there was a correla-
tion between the distribution of the different Candida spe-
cies causing BSI and the use of fluconazole, the DDD of
fluconazole per 1000 patient-days was calculated and
plotted against the type of isolated Candida on a yearly
basis. A logistic regression analysis between C. albicans
rate and fluconazole usage was then performed.P values <
0.05 were considered significant.
All the patients consented to participation in the study
and publication of the results.
Table 1: Patient characteristics of 182 patients with candidemia.
Characteristics C.albicans (n= 74) C. non albicans (n= 108) P value
Male 41 70 NS
Famale 33 38 NS
Age (years) mean ± SD Range 58.4 ± 15.4 64.4 ± 11.4 <0.05
Central venous catheterization 65/74 99/108 NS
Parenteral nutrition 38/74 64/108 NS
Ventilator dependence mean ± SD Range 27.9 ± 23.6 32.6 ± 24.5 NS
Apache II score mean ± SD Range 21.8 ± 7.4 25.6 ± 9.8 NS
Underline disease
Surgery 33/74 40/108 NS
Solid tumor 11/74 35/108 <0.05
Solid organ transplant 8/74 10/108 NS
Trauma 7/74 9/108 NS
Hematological malignancies 6/74 10/108 NS
Burn 4/74 3/108 NS
Others 5/74 1/108 NS
NS = Not significantBMC Infectious Diseases 2006, 6:21 http://www.biomedcentral.com/1471-2334/6/21
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Results
In total, 182 episodes of candidaemia were identified,
with an average incidence of 2.22 episodes/10 000
patient-days/year (range 1.25–3.06 episodes), as shown
in table 1. Incidence of candidemia increased during the
study period from 1.25 in 1999 to 3.06 episodes/10 000
patient-days/year in 2003 (Figure 1). The demographic
and clinical characteristics of the patients are summarized
in table 1. Patients with Candida non-albicans fungemia
were significantly older. There were no significant differ-
ences in sex, age, central venous, catheterization,
parenteral nutrition, ventilator dependence, Apache II
score and other underline disease. Non-albicans candi-
demia are significantly more frequent in patients with
solid tumor. Overall, 40% of the episodes (74/182) were
due to C.albicans, followed by C. parapsilosis(23%), C.gla-
brata (15%), C.tropicalis (9%) and other species (13%)
(Table 2) The percentage of C. albicans which was isolated
in about 60% of the episodes in the first years of study,
progressively dropped to 24%, with a median percentage
year reduction of 13%, while the absolute number and the
incidence of C.albicans  did not vary during the years
observed. The change was statistically significant (K2 =
24.452; p < 0.0001), although in absence of a rigorous lin-
ear trend. Non-albicans strains steadily increased through-
out the study period surpassing C.albicans in the second
half of the study and raising from 21% to 67% (P = 0.01)
(Figure 2). The proportion of non-albicans species went
from 38% and 21% of total isolates in the years 1999–
2000 and then to 67%, 73% and 76% in 2001, 2002 and
2003, respectively. Among non-albicans strains, in 2002
we noted an increase of C.parapsilosis  isolation rates,
which reached 51% of total, while absence of C.tropicalis
was noted in the years 2000–2001.
The use of fluconazole for prophylaxis or therapy
increased four times during the study period. Logistic
regression analysis showed a statistically significant corre-
lation between the shift from albicans to non-albicans
strains and the yearly fluconazole consumption. As
shown in figure 3, an increase of 100 fluconazole DDDs
corresponded to a reduction in the isolation of C. albicans
of 5%.
Discussion
Our study demonstrates a shift in the species of Candida
causing fungemia in a medical and surgical ICU popula-
tion during a 5 year period. The proportion due to C. albi-
cans decreased whereas that due to other species, such as
C. parapsilosis, C. tropicalis and C.glabrata, increased. Such
an increase in non-albicans species was also seen in retro-
spective reviews of candidemias [4,10,12,15,16]. In con-
trast to hematologic patients where a decrease in
C.albicans infection resulted in a significant reduction in
the incidence of candidemia [17], in our experience the
overall incidence actually increased (Table 1; Figure 1).
Traditionally, C.tropicalis has been the second and C.gla-
brata the third or fourth most common Candida species
recovered from blood [4,8]. In our study C.parapsilosis sur-
Table 2: Incidence and distribution of candidemia in the years 1999 – 2003 in S. Martino Hospital ICU expressed in number and 
percentage of isolates. Polymicrobial infections were excluded.
1999 2000 2001 2002 2003 Total
Number of isolates (percentage of species in the year)
C.albicans 13 (62) 26 (79) 11 (33) 12 (27) 12 (24) 74 (40)
C.parapsilosis 2 (9) 0 4 (12) 23 (51) 13 (26) 42 (23)
C. glabrata 0 1 (3) 12 (36) 2 (4) 12 (24) 27 (15)
C. tropicalis 5 (24) 0 0 7 (16) 5 (10) 17 (9)
Othres (C.kruzei, C.guillermondii, C.lusitanae) 1 (5) 6 (18) 6 (19) 1 (2) 8 (16) 24 (13)
Total candidemia 21 33 33 45 50 182
Incidence of candidemia/10 000 patient-days/year 1.25 2 2.05 2.74 3.06 2.22
Incidence of candidemia due to C.albicans/10 000 patient-days/year 0.84 1.58 0.66 0.73 0.73 0.91
 incidence of candidemia episodes/10 000 patient-days/year;  ■  DDD's of fluconazole × 100 pts/days Figure 1
 incidence of candidemia episodes/10 000 patient-days/year; 
■  DDD's of fluconazole × 100 pts/days.
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passed the other non-albicans to become the most com-
mon species isolated after C.albicans. The high incidence
of C.parapsilosis candidemia has been previously reported
in South American hospitals [15,18,19]. The role of C.par-
apsilosis as an exogenous acquired pathogen is well known
and has been associated with parenteral alimentation and
intravascular devices [20], commonly used in critical
patients.
Several investigators postulated that the widespread use of
fluconazole would have selected yeast species intrinsically
resistant or less sensitive to fluconazole, such as Candida
kruzei, C. glabrata or C. tropicalis [21-23]. Some published
reports confirmed this hypothesis, while others did not
[2,24,25]. At the San Martino Hospital, the incidence of
infections caused by most non-albicans Candida species
changed substantially during the study period. These
changes occurred in concomitance with a four fold
increase in the use of fluconazole. In our ICU, during
2001 and the following years, the usage of fluconazole at
dosage of 200–400 mg/day increased because of the
changing in prophylactic strategy in high-risk patients,
according to the efficacy demonstrated in various reports
[26,27]. A logistic regression analysis showed a statisti-
cally significant correlation between the shift from albi-
cans  to non-albicans  strains and the yearly fluconazole
consumption, as shown in figure 2. However, it be recog-
nised that other events might have played a role in the
selection of different species. For example, in the last 2
years of the study, the increased proportion of candi-
demias due to C.parapsilosis, a yeast species almost always
susceptible to fluconazole, is not readily explained by
increased fluconazole use. It is likely that changes in the
proportion of fungemias due to C. parapsilosis reflect noso-
comial acquisition of this species.
In ICU, the role for the use of fluconazole remains contro-
versial, since fluconazole was demonstrated to reduce the
incidence of Candida infections in a particular group of
high-risk patient population [26-28].
Though limited by its retrospective nature, our study
focuses the attention on predominance of non-C.albicans
isolates, usually less susceptible or intrinsically resistant to
fluconazole.
It is well known that positive blood culture for Candida
spp. is a life threatening situation, requiring an empirical
antifungal treatment which should started with the appro-
priate agents as soon as possible. Therefore the knowledge
of the local epidemiological trends in Candida species iso-
lated in blood cultures is important to guide therapeutic
choices.
The data we have reported are based on records from the
microbiology laboratory, and thus, have certain inherent
limitations. Our study did not address specific risk factors,
which undoubtedly play a role in the selection of species
causing fungemia. However, this type of study does reveal
overall long-term trends that should be helpful to physi-
cians and antibiotic use committees in establishing guide-
lines for the appropriate use of antifungal agents.
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Correlation using logistic regression between percentage 
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Line plot representation of Candida albicans and Candida non- albicans isolates rates during the study period Figure 2
Line plot representation of Candida albicans and Candida non-
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